ArticleAIDS (London, England)2026
Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended for first-line antiretroviral therapy (ART), and for suppressed switching, in combination with a two nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone. Doravirine does not have a high barrier to resistance, and genotypic resistance testing (GRT) preswitch is recommended. Data on its use without preswitching GRT is limited. This retrospective cohort study presents data on doravirine use in virologically suppressed people with and without prior GRT.
methodsA retrospective single-center review of health records was conducted among prescribed doravirine-based ART at a London HIV service.
resultsOf the 582 adults included, 75% were men, 56% were of White ethnicity. The median age at baseline was 51 years (IQR: 44-58). Median time on doravirine was 127 weeks (IQR: 93-175). GRT showing no doravirine resistance was available for 78% ( n = 454) of individuals before switching to doravirine, of whom 2% experienced virological failure ( n = 9), including two people with NNRTI and NRTI resistance. Among those without preswitching GRT ( n = 97), 1% experienced virological failure ( n = 1), with NNRTI and NRTI resistance. There was no statistical significant difference in virologic suppression (viral load <50 copies/ml) rates (GRT 95% versus no-GRT 95%; P = 0.823). A similar proportion of people with (24%) and without (27%) preswitching GRT switched away from doravirine, most commonly due to adverse effects.
conclusionWe did not find differences in efficacy and tolerability in people switched to doravirine-based ART with or without GRT. As expected, emergent NNRTI and NRTI resistance was common amongst those with virological failure on doravirine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.